Vol. IV · No. 19
Tuesday, June 23, 2026
Issue: Spring · 2026
Established · MMXXVI
Geroevidence
— The evidence base for longevity medicine —
Indexed by PubMed · CTG · Cochrane
Editorial team · geroevidence.com
Subscription · app.geroevidence.com
Geroevidence · Editorial desk

From the editorial desk

Evidence analysis, trial updates, and longevity science — reviewed before publication.

21 articles published · 5 categories · Updated continuously
§ Categories · 5
01
Intervention Profiles
7 articles
02
Clinical Trials
3 articles
03
Evidence Analysis
6 articles
04
Longevity Science
3 articles
05
Editorial
2 articles
§ All articles · newest first
Evidence Analysis
The best-evidenced longevity drugs in 2026, ranked by trial data
Every longevity compound currently tracked on Geroevidence, ranked by evidence strength rather than hype — from Phase III outcome trials down to early-stage signals.
June 24, 2026  ·  12 min read
Clinical Trials
Could semaglutide become an anti-aging drug? The SELECT trial and beyond
Semaglutide's weight-loss story is well known. The cardiovascular outcome data is the more significant — and less discussed — longevity story.
June 24, 2026  ·  11 min read
Evidence Analysis
Why most longevity supplements lack human trial data
A structural explanation of why most longevity supplements have animal data but not human outcome trials — and how to tell the difference when evaluating a claim.
June 24, 2026  ·  8 min read
Longevity Science
Epigenetic clocks explained: what biological age tests can and can't tell you
Direct-to-consumer biological age tests have become a popular longevity-adjacent product. Here is what the underlying science measures, and what it doesn't yet validate.
June 24, 2026  ·  9 min read
Longevity Science
Is longevity medicine legitimate? What the research community actually says
The field spans serious NIH-funded geroscience and unregulated supplement marketing, often using the same vocabulary. Distinguishing them requires looking at specific claims, not the field as a whole.
June 24, 2026  ·  9 min read
Evidence Analysis
NAD+ IV therapy vs. NMN and NR supplements: comparing the evidence
NAD+ IV drips have become a popular wellness-clinic offering. Here is how the evidence for IV NAD+ compares to oral NMN and NR precursors.
June 24, 2026  ·  10 min read
Clinical Trials
Rapamycin dosing in published clinical trials: what the research has actually tested
A summary of dosing regimens used in published rapamycin longevity trials. This describes what researchers have studied — it is not a dosing recommendation.
June 24, 2026  ·  10 min read
Evidence Analysis
Berberine vs. metformin: is "nature's Ozempic" backed by longevity evidence?
Berberine has been called "nature's Ozempic" online. Here is how its actual human trial evidence compares to metformin's.
June 24, 2026  ·  10 min read
Intervention Profiles
Spermidine and autophagy: what the human evidence actually shows
A naturally occurring polyamine, studied for the same autophagy pathway that gives rapamycin its mechanistic case — with a much earlier-stage human evidence base.
June 24, 2026  ·  8 min read
Intervention Profiles
Acarbose for longevity: the ITP mouse data and human diabetes evidence
A decades-old diabetes drug extends lifespan in a rigorous mouse program — but its human longevity evidence tells a different, more limited story.
June 24, 2026  ·  9 min read
Evidence Analysis
Dasatinib + quercetin vs. fisetin: comparing the senolytic evidence
A direct comparison of the two leading senolytic approaches — mechanism, current human trial data, and evidence strength, rated honestly.
June 23, 2026  ·  11 min read
Intervention Profiles
17α-Estradiol: a lifespan effect with a sex-specific puzzle
A non-feminizing estrogen extends lifespan in male mice in NIA-backed data — and shows no comparable effect in females. What the evidence shows, and what remains unexplained.
June 23, 2026  ·  10 min read
Intervention Profiles
Taurine and longevity: what the evidence actually shows
A 2023 mouse study reignited interest in an amino acid most people associate with energy drinks. Here is what the data shows, what it doesn't, and why Geroevidence hasn't assigned it an evidence tier yet.
June 23, 2026  ·  9 min read
Intervention Profiles
Rapamycin for longevity: what the clinical evidence actually shows in 2026
A structured synthesis of every published human trial and major animal study — evidence strength rated honestly, with what is known, what is unknown, and what trials are ongoing.
May 13, 2026  ·  14 min read
Intervention Profiles
GLP-1 agonists beyond weight loss: the cardiovascular and longevity evidence
Semaglutide and tirzepatide are the most prescribed drugs in medicine. The weight loss story is well known. The cardiovascular and longevity evidence is more important and less understood.
May 13, 2026  ·  12 min read
Intervention Profiles
SGLT2 inhibitors and aging: what the evidence actually shows
Empagliflozin and dapagliflozin have some of the strongest cardiovascular and renal outcomes data in medicine. Their longevity relevance is underappreciated. Here is the evidence.
May 13, 2026  ·  10 min read
Clinical Trials
The TAME trial explained: what metformin's biggest longevity test will actually tell us
TAME is the most significant longevity trial running. What the trial design means, what a positive result would and would not prove, and what interim signals look like.
May 10, 2026  ·  11 min read
Evidence Analysis
NMN vs NR: comparing the evidence for the two main NAD+ precursors
A direct head-to-head comparison of every published human trial for NMN and NR — evidence rated honestly, and what the first head-to-head trial will tell us.
May 8, 2026  ·  9 min read
Longevity Science
The hallmarks of aging explained: a clinical reference
The twelve hallmarks of aging are the biological framework underlying every intervention in the longevity pharmacopeia. What each hallmark is, why it matters clinically, and which interventions target it.
May 7, 2026  ·  16 min read
Editorial
Why Geroevidence exists
A statement of purpose — what we are building, who it is for, and what we will never claim to be.
May 6, 2026  ·  5 min read
Editorial
How Geroevidence came to be
The origin of a clinical evidence platform — built not by a physician, but by someone who works inside the healthcare system and grew tired of watching good science reach clinicians poorly.
May 5, 2026  ·  6 min read